HomeCompareNTUS vs KMB

NTUS vs KMB: Dividend Comparison 2026

NTUS yields 6.07% · KMB yields 5.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 KMB wins by $16.0K in total portfolio value
10 years
NTUS
NTUS
● Live price
6.07%
Share price
$32.96
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$29.9K
Annual income
$893.24
Full NTUS calculator →
KMB
KMB
● Live price
5.25%
Share price
$96.47
Annual div
$5.06
5Y div CAGR
17%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$45.9K
Annual income
$5,211.33
Full KMB calculator →

Portfolio growth — NTUS vs KMB

📍 KMB pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNTUSKMB
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NTUS + KMB cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NTUS pays
KMB pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NTUS
Annual income on $10K today (after 15% tax)
$515.78/yr
After 10yr DRIP, annual income (after tax)
$759.25/yr
KMB
Annual income on $10K today (after 15% tax)
$445.84/yr
After 10yr DRIP, annual income (after tax)
$4,429.63/yr
At 15% tax rate, KMB beats the other by $3,670.38/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NTUS + KMB for your $10,000?

NTUS: 50%KMB: 50%
100% KMB50/50100% NTUS
Portfolio after 10yr
$37.9K
Annual income
$3,052.28/yr
Blended yield
8.06%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on KMB right now

NTUS
Analyst Ratings
3
Buy
2
Hold
Consensus: Buy
KMB
Analyst Ratings
9
Buy
19
Hold
3
Sell
Consensus: Hold
Price Target
$123.00
+27.5% upside vs current
Range: $102.00 — $162.00
Altman Z
3.4
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NTUS buys
0
KMB buys
6
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$KMB▼ Sell$1,001 - $15,0002025-11-12
Ro Khanna🏢 House$KMB▼ Sell$1,001 - $15,0002025-09-29
Ro Khanna🏢 House$KMB▼ Sell$1,001 - $15,0002025-09-05
Lisa McClain🏢 House$KMB▼ Sell$1,001 - $15,0002025-07-16
Lisa McClain🏢 House$KMB▲ Buy$1,001 - $15,0002025-07-10
Rob Bresnahan🏢 House$KMB▼ Sell$1,001 - $15,0002025-05-15
Rob Bresnahan🏢 House$KMB▼ Sell$1,001 - $15,0002025-04-08
Julie Johnson🏢 House$KMB▼ Sell$1,001 - $15,0002025-04-01
Ro Khanna🏢 House$KMB▲ Buy$1,001 - $15,0002024-11-15
Tommy Tuberville🏛 Senate$KMB▼ Sell$15,001 - $50,0002024-10-29
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNTUSKMB
Forward yield6.07%5.25%
Annual dividend / share$2.00$5.06
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%17%
Portfolio after 10y$29.9K$45.9K
Annual income after 10y$893.24$5,211.33
Total dividends collected$7.5K$21.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyHold

Year-by-year: NTUS vs KMB ($10,000, DRIP)

YearNTUS PortfolioNTUS Income/yrKMB PortfolioKMB Income/yrGap
1← crossover$11,307$606.80$11,314$613.68$7.00KMB
2$12,739$641.21$12,865$759.19$126.00KMB
3$14,306$675.19$14,709$943.96$403.00KMB
4$16,017$708.64$16,919$1,180.17$902.00KMB
5$17,879$741.44$19,588$1,484.33$1.7KKMB
6$19,904$773.52$22,838$1,879.06$2.9KKMB
7$22,102$804.79$26,832$2,395.60$4.7KKMB
8$24,485$835.20$31,788$3,077.63$7.3KKMB
9$27,063$864.70$38,000$3,986.82$10.9KKMB
10$29,851$893.24$45,872$5,211.33$16.0KKMB

NTUS vs KMB: Complete Analysis 2026

NTUSStock

Natus Medical Incorporated provides medical device solutions focuses on the diagnosis and treatment of patients with central nervous and sensory system disorders worldwide. It offers products and technologies used for the screening, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological and neurosurgical treatments, epilepsy, sleep disorders, and neuromuscular diseases. The company also provides computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology; and software systems for managing and tracking disorders and diseases for public health laboratories. In addition, it offers electroencephalography, long term monitoring, intensive care unit monitoring, electromyography, sleep analysis or polysomnography, and intra-operative monitoring solutions. Further, the company provides hearing assessment, screening, and instrument fitting solutions; jaundice management products; brain injury products; and eye imaging systems and products used in the advanced science and practice of neonatal and pediatric retinal imaging. Additionally, it offers essential products used in the everyday operation of neonatal intensive care unit (NICU); balance assessment systems to evaluate patients with balance disorders; and NICVIEW, a live streaming video for families with babies in the NICU. The company also provides computer-based audiological, otoneurologic, and vestibular instrumentation for hearing and balance care professionals. It serves university medical centers, public and private hospitals, physician offices, clinics, research laboratories, and others. The company was formerly known as ALGOTEK Instruments, Inc. and changed its name to Natus Medical Incorporated in September 1988. Natus Medical Incorporated was incorporated in 1987 and is headquartered in Middleton, Wisconsin.

Full NTUS Calculator →

KMBConsumer Staples

Kimberly-Clark Corporation, together with its subsidiaries, manufactures and markets personal care and consumer tissue products worldwide. It operates through three segments: Personal Care, Consumer Tissue, and K-C Professional. The Personal Care segment offers disposable diapers, swimpants, training and youth pants, baby wipes, feminine and incontinence care products, and other related products under the Huggies, Pull-Ups, Little Swimmers, GoodNites, DryNites, Sweety, Kotex, U by Kotex, Intimus, Depend, Plenitud, Softex, Poise, and other brand names. The Consumer Tissue segment provides facial and bathroom tissues, paper towels, napkins, and related products under the Kleenex, Scott, Cottonelle, Viva, Andrex, Scottex, Neve, and other brand names. The K-C Professional segment offers wipers, tissues, towels, apparel, soaps, and sanitizers under the Kleenex, Scott, WypAll, Kimtech, and KleenGuard brands. The company sells household use products directly to supermarkets, mass merchandisers, drugstores, warehouse clubs, variety and department stores, and other retail outlets, as well as through other distributors and e-commerce; and away-from-home use products directly to manufacturing, lodging, office building, food service, and public facilities, as well as through distributors and e-commerce. Kimberly-Clark Corporation was founded in 1872 and is headquartered in Dallas, Texas.

Full KMB Calculator →
📬

Get this NTUS vs KMB comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NTUS vs SCHDNTUS vs JEPINTUS vs ONTUS vs KONTUS vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.